Bioequivalence testing over new combination drugs to be made compulsory next July

The Korea Food and Drug Administration announced that drug makers are required to conduct bioequivalence tests for new combination medicines from July next year as part of its efforts laid the foundation for Korean pharmaceutical companies to be able to comply with international GMP (good manufacturing practices).

Under the newly formulated regulation, a total of 560 conventional medicines w...